GILD - Gilead Sciences, Inc.
| Previous Close | 76.31 |
| Open | 76.00 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1200 |
| Day's Range | 75.14 - 76.29 |
| 52 Week Range | 64.27 - 89.54 |
| Volume | 4,075,281 |
| Avg. Volume | 6,370,215 |
| Market Cap | 98.029B |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | 45.17 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.28 (3.10%) |
| Ex-Dividend Date | 2018-09-13 |
| 1y Target Est | N/A |
- Motley Fool•yesterday
Can This Tiny Biotech Revolutionize a $35 Billion Market?
This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.
Motley Fool•2 days agoForget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock
Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.
Market Realist•2 days agoGauging Analysts’ Views of Sarepta Stock in October
Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.
- Yahoo Finance•2 days ago
Trump administration: Drug makers should disclose prices in TV ads
just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.
Market Realist•3 days agoA Look at Sarepta Therapeutics’ Stock Performance
Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.
Market Realist•3 days agoKey Collaborations Bode Well for Sarepta Therapeutics
Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.
- Motley Fool•3 days ago
2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better
A bad week for the broad market made some generous payouts even more attractive.
Market Realist•3 days agoAnalyzing Sarepta’s Product Pipeline
Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.
- Zacks•5 days ago
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.
Market Realist•5 days agoUnderstanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.
- American City Business Journals•6 days ago
Why a Peninsula cancer fighter soared nearly 40% after record-breaking IPO
As the market fell sharply Thursday, this biotech boomed after raising $324 million in an initial public offering.
Market Realist•7 days agoHealthcare Stocks in the Red amid Broader Market Sell-Off
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
- Zacks•8 days ago
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
- Zacks•8 days ago
Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
Data presentations by leading sector players take center stage this week.
- Market Realist•8 days ago
Celgene: Analysts’ Views before Its Third-Quarter Earnings
Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.
- Motley Fool•8 days ago
Better Buy: Crispr Therapeutics AG vs. Editas
Which gene editing start-up has the best chance to outperform in the years ahead?
- Simply Wall St.•9 days ago
Estimating The Intrinsic Value Of Gilead Sciences Inc (NASDAQ:GILD)
How far off is Gilead Sciences Inc (NASDAQ:GILD) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...
Market Realist•10 days agoGilead Sciences Stock: Analysts’ Recommendations
In October, of the 28 analysts covering Gilead Sciences (GILD), 18 analysts gave the stock a “buy” or higher rating, while ten analysts gave the stock a “hold” rating. The mean rating for Gilead Sciences stock is 2.14 with a target price of $87.96, which implies an upside potential of 14.9% over the company’s closing price of $76.56 on October 4.
Market Realist•10 days agoTaking Stock of Gilead’s Operational Performance
Gilead Sciences’ (GILD) selling, general, and administrative expenses increased from $897.0 million in the second quarter of 2017 to $980.0 million in the second quarter. The increase was due to higher stock-based compensation expenses and costs after the Kite acquisition.
- Zacks•12 days ago
Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know
In the latest trading session, Gilead Sciences (GILD) closed at $76.24, marking a -0.24% move from the previous day.
- Market Realist•12 days ago
Cara Therapeutics: Performance and Estimates for Q3
Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.
Market Realist•13 days agoGilead Sciences: What to Expect from the Top Line
Gilead Sciences (GILD) generated total revenues of $5.65 billion in the second quarter—compared to $7.14 billion in the second quarter of 2017. The company generates revenues from sales of products and royalties and contract arrangements. Gilead Sciences’ product sales decreased from $7.05 billion in the second quarter of 2017 to $5.54 billion in the second quarter. The company’s royalty, contract, and other revenues increased from $95.0 million in the second quarter of 2017 to $108.0 million in the second quarter.
Market Realist•13 days agoAnalyzing Gilead Sciences’ Research Pipeline Developments
On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.
- Market Realist•13 days ago
How’s Gilead Sciences Positioned in October?
For Gilead Sciences (GILD), falling revenues and recent gains in the stock price have kept investors interested in the stock. A slew of key collaboration and licensing arrangements have piqued investors’ interest in the company’s research programs.
- Zacks•13 days ago
Gilead Announces Positive Data From Ongoing Biktarvy Study
Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.
